Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IM CannabisIMCC -12.06%37 Cash-to-Debt is 0.12 as of Jun. 2026, which is 43% below its 10-year median of 0.21. GuruFocus rates IMCC with a GF Score™ of 37/100 and a GF Value™ of $23.67 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 983 Drug Manufacturers companies, IM Cannabis ranks worse than 83.83% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. IM Cannabis's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.12.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, IM Cannabiscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for IM Cannabis's Cash-to-Debt or its related term are showing as below:
IMCC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.21 Max: No Debt
Current: 0.12
During the past 13 years, IM Cannabis's highest Cash to Debt Ratio was No Debt. The lowest was 0.04. And the median was 0.21.
IMCC's Cash-to-Debt is ranked worse than 83.83% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs IMCC: 0.12
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
IM Cannabis Cash-to-Debt Related Terms
IM Cannabis Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for IM Cannabis's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, IM Cannabis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IM Cannabis Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IM Cannabis's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where IM Cannabis's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IM Cannabis (IMCC) has a Cash-to-Debt of 0.12 as of Jun. 2026. This is 43% below median its historical median of 0.21. Over the past decade, IM Cannabis' Cash-to-Debt has ranged from 0.04 to 10,000.00. According to the industry distribution chart, IM Cannabis ranks #824 out of 983 companies in the Drug Manufacturers industry, placing it in the top 83.8%.
Is IM Cannabis' Cash-to-Debt too high?
IM Cannabis' current Cash-to-Debt of 0.12 is 43% below median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.96. IM Cannabis' value of 0.12 is 87.5% below this industry median. Based on the distribution chart, IM Cannabis ranks #824 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, IM Cannabis has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IM Cannabis' Cash-to-Debt compare to SHPH and PLSH?
According to the Drug Manufacturers industry distribution chart, IM Cannabis ranks #824 out of 983 companies for Cash-to-Debt. This places IM Cannabis in the lower half of its industry. The industry median Cash-to-Debt is 0.96. IM Cannabis' value of 0.12 is 87.5% below this benchmark. Historically, IM Cannabis' own Cash-to-Debt has ranged from 0.04 to 10,000.00 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.96, IM Cannabis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IM Cannabis's current Cash-to-Debt of 0.12 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IM Cannabis's current Cash-to-Debt is 0.12, which is 43% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IM Cannabis stock overvalued right now?
Based on GuruFocus' analysis, IM Cannabis (IMCC) is currently considered Possible Value Trap. The stock's GF Value™ is $23.67, compared to a current price of $1.75 — trading 92.6% below its estimated fair value. The current Cash-to-Debt is 0.12, which is 43% below median its 10-year median of 0.21 and 87.5% below the Drug Manufacturers industry median of 0.96. IM Cannabis' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For IM Cannabis (IMCC), the current Cash-to-Debt is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IM Cannabis (IMCC) Overvalued in 2026?
Based on GuruFocus' analysis, IM Cannabis stock appears to be undervalued.
The current stock price of $1.75 is trading 92.6% below its estimated GF Value™ of $23.67.
GuruFocus considers IM Cannabis to be Possible Value Trap.
Key valuation signals for IMCC:
Cash-to-Debt: 0.12 (43% below median its 10-year median of 0.21)
GF Value™: $23.67 vs. price of $1.75 (92.6% below fair value)
Industry Position: 87.5% below the Drug Manufacturers median (#824 of 983)
No single metric tells the full story. See the IMCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
37GF Score
Get the complete analysis for IMCC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCC has been successfully added to your 
